Subscribe
e.g. organoids

Axol Bioscience Introduces CiPA-Validated Human Stem Cell-Derived Ventricular Cardiomyocytes to Help Improve Drug Discovery

Axol Bioscience Ltd. announced that its hiPSC-derived ventricular cardiomyocytes have undergone comprehensive in vitro pro-arrhythmia assay (CiPA) validation.
[Axol Bioscience Ltd (THE SCIENTIST)]
Press Release
Published In
NewslettersESC & iPSC NewsMuscle Cell News
spot_img

Stay up-to-date with your field!

Subscribe for free weekly science newsletters.

Related News

Stem Cell-Based Therapy for Human Diseases

[Signal Transduction and Targeted Therapy] Scientists provide an update on recent clinical applications using either human pluripotent stem cells or mesenchymal stem cells derived from bone marrow, adipose tissue, or the umbilical cord for the treatment of human diseases.
Cell Therapy NewsESC & iPSC NewsMesenchymal Cell NewsNewsletters
Read more

Extracellular Vesicles Derived from Wharton’s Jelly Mesenchymal Stem Cells Inhibit the Tumor Environment via the miR-125b/HIF1α Signaling Pathway

[Scientific Reports] The authors suggested a novel strategy to treat triple negative breast cancer (TNBC) using mesenchymal stem cell-derived extracellular vesicles to transform the behaviors and cellular communication of TNBC cells with other non-cancer cells related to tumorigenesis and metastasis.
Cell Therapy NewsMammary Cell NewsMesenchymal Cell NewsNewsletters
Read more

Modulation of BCL-2 in Both T Cells and Tumor Cells to Enhance Chimeric Antigen Receptor T Cell Immunotherapy against Cancer

[Cancer Discovery] Researchers combined CAR T19 with the FDA-approved BCL-2-inhibitor, venetoclax, and demonstrated in vivo synergy in venetoclax-sensitive non-Hodgkin lymphoma.
Cell Therapy NewsNewsletters
Read more
Brought to you by